Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat

This article was originally published on ETFTrends.com. Stocks rallied Wednesday, a day after one of the most contentious midterm elections in U.S. history. In Tuesday’s midterm elections, Democrats emerged with control of the House while Republicans maintained control of the Senate. Among the winning exchange traded funds Wednesday were biotechnology funds, including the SPDR S&P Biotech ETF (NYSEArca: XBI), which […]

Read more

Why Clearside Biomedical Shares Were Halved

Clearside Biomedical Inc. (NASDAQ: CLSD) shares dropped sharply early on Monday after the firm reported results from its late-stage Sapphire trial. Ultimately, the Phase 3 results did not achieve the primary endpoint for the treatment of retinal vein occlusion (RVO). The primary endpoint of this trial was the proportion of patients in the combination treatment arm, compared to the intravitreal […]

Read more

Melinta Therapeutics Loses Again Despite Positive Phase 3 Results

Melinta Therapeutics Inc. (NASDAQ: MLNT) shares dropped on Monday despite the company announcing positive top-line results from its Phase 3 trial of Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP). Baxdela was compared to the standard of moxifloxacin across the board in this trial. Baxdela met all key primary and secondary endpoints in the trial, […]

Read more

Why Mirati Therapeutics Is Sinking

Mirati Therapeutics Inc. (NASDAQ: MRTX) shares dropped on Monday after the company announced updated positive clinical data from its midstage study in non-small cell lung cancer (NSCLC). The data were presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Germany. Specifically, the firm announced updated data from its ongoing Phase 2 clinical trial of sitravatinib in combination […]

Read more

Why Proteostasis Shares Are Skyrocketing

Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares absolutely exploded on Thursday after the company announced positive preliminary results from its early-stage cystic fibrosis (CF) trial. The positive preliminary results are coming from three doublet cohorts of the company’s ongoing Phase 1 studies of the company’s proprietary combination therapy doublet, PTI-808 and PTI-801, in subjects with CF. These studies were designed to […]

Read more

Akcea Stumbles Over Newest Board Addition

Akcea Therapeutics Inc. (NASDAQ: AKCA) shares pulled back on Monday after the company announced a big change to its board of directors. With this change, Akcea’s management acknowledges that the company is entering a new phase of commercializing drugs with the global approval and launch of Tegsedi (inotersen). The company announced that Damien McDevitt, Ph.D. chief business officer (CBO) of […]

Read more

Healthcare: 2 Hot Biotech Stocks on Our Radar

There are lots of exciting biotech stocks that investors can consider owning in their growth portfolios. But according to Motley Fool Industry Focus: Healthcare analyst Shannon Jones and Fool contributor Todd Campbell, Neurocrine Biosciences (NASDAQ: NBIX) and Regenxbio (NASDAQ: RGNX) are two stocks that ought to be top of mind. Neurocrine Biosciences is already racking up significant revenue growth from […]

Read more

Can GTx Make It Past This Enobosarm Study?

GTx Inc. (NASDAQ: GTXI) shares were absolutely crushed on Friday after the company announced results from its midstage trial in post-menopausal women with stress urinary incontinence. Unfortunately, the Phase 2 trial of enobosarm did not achieve statistical significance on the primary endpoint of the proportion of patients with a greater than 50% reduction in incontinence episodes per day compared to […]

Read more

How Adverum Bio Is Winning With FDA Update

Adverum Biotechnologies Inc. (NASDAQ: ADVM) shares made a handy gain on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA). The FDA granted a Fast Track designation for ADVM-022, for the treatment of wet age-related macular degeneration (wAMD). A Fast Track Designation is intended to facilitate the development and expedite the review of […]

Read more
1 2 3